Claim Missing Document
Check
Articles

Found 4 Documents
Search

The Levels of Physician Disaster Preparedness Based on the Tsunami Vulnerability Zones in Banda Aceh Taufik Suryadi; Balqis Qonita; Hafni Andayani; Agung Pranata
International Journal of Disaster Management Vol 5, No 1 (2022): April
Publisher : TDMRC, Universitas Syiah Kuala

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1241.754 KB) | DOI: 10.24815/ijdm.v5i1.22207

Abstract

Disasters caused by natural hazards may harm the health sector. It needs physician preparedness as a significant step in disaster risk reduction efforts and is expected to obtain an adequate response when a disaster occurs. This study aimed to determine the level of physician preparedness at the public health center (PHC) to face a tsunami caused by an earthquake based on the vulnerability zones. This research method is observational analytic with a cross-sectional design using a questionnaire developed by LIPI-UNESCO/ISDR adjusted to the core competencies and sub-competencies for disaster medicine and public health. The samples were collected in total sampling. The results show that most respondents have a preparedness index with categories almost prepare and not prepare, each of 12 respondents from a total of 42 people who participated in this study (28.56%). The physician from zone III has the best preparedness, and the physician from zone I are at least prepared for disasters. Statistical analysis using the Kruskal Wallis test obtained p-value 0.646 (p 0.05). The conclusion was found that there was no significant difference between the levels of physician preparedness at the PHC facing tsunami disasters based on the tsunami vulnerability zone in Banda Aceh. 
Characteristics of Patients with Non-Malignant Pleural Effusion in dr. Zainoel Abidin Hospital Banda Aceh in 2019 Putra, Teuku Romi Imansyah; Maya, Price; Hasan, Maryatun; Pranata, Agung; Salsabila, Safira; Sariningrum, Hesti Ariandani
Jurnal Penyakit Dalam Indonesia Vol. 9, No. 1
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Introduction. Pleural effusion occurs when there is a pathological process causing fluid to accumulate in the pleural cavity. Pleural effusion is still the main cause of respiratory distress and can also be caused by many diseases either from pleural, lungs, or even extrapulmonary problems. The morbidity and mortality of this condition are directly associated with the underlying causes. The aim of this study is to investigate the profile of the patients, etiology, location, fluid characteristics, comorbidities, and also the bacteria pattern of non-malignant pleural effusion. Methods. This is a retrospective descriptive study thatused patient’s medical records from January to December 2019 in Zainoel Abidin Hospital, Banda Aceh as the source of data for this study. Results. There were 118 patients with non-malignant pleural effusion from January to December 2019. In this study, it was found that the highest gender was male (66.9 %) and in the age group of 46-55 and >65 years old in male, and 56-66 years old in female. The most frequent etiology of non-malignant pleural effusion was pneumonia. The majority (72.9%) of pleural effusion were exudate and mostly happened in the right lung (53.4%). Comorbidities were found in 104 patients and the main comorbiditywas tuberculosis (11.3%). The result of the pleural fluid culture test showed that there were 33 samples with positive results. Staphylococcus hominis was the bacteria found in most of the isolates (22.9%).Conclusion. Non-malignant pleural effusions are generally exudates with Staphylococcus hominis being the most common bacterial growth
Treatment acceptance and its associated determinants in cancer patients: A systematic review Novirianthy, Rima; Syukri, Maimun; Gondhowiardjo, Soehartati; Suhanda, Rachmad; Mawarpury, Marty; Pranata, Agung; Renaldi, Teuku
Narra J Vol. 3 No. 3 (2023): December 2023
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v3i3.197

Abstract

Treatment recommendations for cancer patients are carried out according to clinical assessment, type and stage of cancer and treatment guidelines. However, many patients do not accept the recommendations. This raises obstacles in managing of cancers, which not only affects the patients, but also the family and people around the patients. This problem could increase morbidity, mortality and recurrence rate, which might result in lower quality of life. Since this condition is a complex problem, there is necessity to explore and determine various determinants from different levels. The aim of this systematic  review was to explore the acceptances of cancer treatments among cancer patients and its associated determinants. Articles published from 2010 to 2023 were searched in four databases: ScienceDirect, Medline, Google Scholar and PubMed. Articles written in English and focussing on three main cancer treatments (surgery, chemotherapy and radiotherapy) were eligible.  A narrative approach was used and the data were analysed into selected themes. Data suggest that several factors influence patient acceptance for cancer therapy including sociodemographic, economic and spiritual cultural backgrounds; patient knowledge and perceptions; community support, as well as policy and availability of health facilities.  The determinants consist of individual, interpersonal, institutional, community and public policy level and interaction between levels are contributing to cancer treatment acceptance. In conclusion, cancer treatment acceptance remains a problem in particular in low middle income countries. In addition, the data on radiotherapy referral acceptance were limited and needed further study.
Comparative study of anti-SARS-CoV-2 receptor-binding domain total antibody titer before and after heterologous booster with mRNA-based COVID-19 vaccine Kamil, Qatrunnada; Putri, Widia; Ayulinda, Arianisah P.; Maelani, Imelda; Anwar, Samsul; Ichsan, Ichsan; Pranata, Agung; Mudatsir, Mudatsir; Syukri, Maimun; Rizal, Samsul; Kurniawan, Rudi; Sofyan, Sarwo E.; Harapan, Harapan
Narra J Vol. 4 No. 3 (2024): December 2024
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v4i3.788

Abstract

The waning immunity following the COVID-19 vaccination become a significant concern and the immunological dynamics of vaccine-induced antibodies after vaccination need to be explored. The aim of this study was to compare anti-SARS-CoV-2 receptor-binding domain (RBD) antibody levels before and after a booster dose with heterologous COVID-19 vaccine and to identify factors influencing the levels after receiving the booster dose. A cross-sectional study was conducted in which individuals who received primary doses of CoronaVac and a booster dose with an mRNA-based vaccine were recruited using a purposive sampling technique. The titers of anti-SARS-CoV-2 RBD antibodies were measured using an enzyme-linked immunosorbent assay (ELISA), and plausible associated factors were collected using a questionnaire-assisted face-to-face interview. The Wilcoxon test was used to compare the titers before and after the booster dose, while the Kruskal-Wallis and Mann-Whitney tests, followed by multivariate linear regression, were used to assess the factors associated with RBD total antibody titers. The results showed that there was a significant increase of anti-SARS-CoV-2 RBD total antibody titers before and after receiving the booster dose (1,558.7 BAU/mL vs 140.6 BAU/mL, p<0.001). The analysis revealed that age (p=0.555), sex (p=0.254), type of vaccine (p=0.914), presence of hypertension (p=0.541), diabetes (p=0.975), chronic obstructive pulmonary disease (COPD, p=0.620), and gout (p=0.364) were not associated with anti-SARS-CoV-2 RBD total antibody titers. However, the titers of anti-SARS-CoV-2 RBD total antibody were significantly different between those with and without hyperlipidemia (p=0.021). This study suggests that a booster dose with a heterologous COVID-19 vaccine could significantly enhance immune responses against COVID-19, and therefore, this strategy may be recommended as part of preventive measures to strengthen immunity against COVID-19.